| Project/Area Number |
62480191
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
内科学一般
|
|---|
| Research Institution | Sapporo Medical College |
|---|
Principal Investigator |
YACHI Akira Professor, Dept. Int. Med., Sapporo Medical College, 医学部, 教授 (50045324)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ENDO Takao Instructor, Dept. Int. Med., Sapporo Medical College, 医学部, 助手 (40191928)
SUGIYAMA Toshiroh Instructor, Dept. Int. Med., Sapporo Medical College, 医学部, 助手 (00196768)
HINODA Yuji Instructor, Dept. Int. Med., Sapporo Medical College, 医学部, 助手 (10165128)
IMAI Kohzoh Assist. Prof., Dept. Int. Med., Sapporo Medical College, 医学部, 講師 (60117603)
加藤 康夫 札幌医科大学, 医学部, 助手 (90185877)
|
|---|
| Project Period (FY) |
1987 – 1988
|
| Project Status |
Completed (Fiscal Year 1988)
|
| Budget Amount *help |
¥4,000,000 (Direct Cost: ¥4,000,000)
Fiscal Year 1988: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1987: ¥3,000,000 (Direct Cost: ¥3,000,000)
|
|---|
| Keywords | anti-idiotypic antibody / Monoclonal antibody / autoimmune disease |
|---|
| Research Abstract |
Model experiments using anti HLA monoclonal antibodies were performed to apply the immune response of anti-idiotypic antibodies to immunotherapy since anti-idiotypic antibodies are of interest in the investigation of a new immunotherapy since anti-idiotypic antibodies are of interest in the investigation of a new immunomodulator for cancer patients.
Polyclonal anti-idiotypic antisera and anti-idiotypic monoclonal antibodies induced with anti HLA-A2. A28 monoclonal antibody KS1.
The antigen rercognized by mouse monoclonal antibody YH206 (MoAb YH206) is mainly expressed in adenocarcinomas and also detected in the sera of cancer patients. Polyclonal and syngeneic monoclonal anti-idiotype antibodies were produced by immunization of MoAb YH206 (IGM) to a rabbit and a BALB/c mouse, respectively. Enzyme immunoassay showed that the anti-idiotype antibodies reacted specifically with MoAb YH206, but had no cross-reactivity with other monoclonal antibodies. Furthermore, the antibodies strongly inhibited the YH206 antigen-antibody reaction.
By using these anti-idiotype antibodies, we screened sera of normal individuals and cancer patients with or without YH206 antigen for the detection of anti-YH206 antibody. Our study revealed that anti-YH206 antibody was detected in the sera of cancer patients, especially stomach and pancreas cancer patients but not in normal individuals. The results suggest that there may be an immune response against adenocarcinoma-associated antigen YH206 in cancer patients.
|
